Regeneron posted its Eylea updates as the company reported ... cholesterol med Praluent, suffered a 19% sales decline to $57 million in the U.S. The company also shares sales on the immunology ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Regeneron’s shares have lost 14.1% year to date compared with the industry’s decline of 4.7%. Eylea’s sales in the United States plunged 39% year over year to $736 million, primarily due to ...

REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.

Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion ...

Starting in 2025, the Eylea franchise as a whole began to decline due to ... We assign Regeneron a Medium Morningstar Uncertainty Rating, as its future sales are well diversified with several ...